ROSUVASTATIN VA UNING FENOFIBRIK KISLOTA BILAN KOMBINATSIYASI ENDOVASKULYAR ARALASHUVDAN KEYIN KEKSA YOSHDAGI BEMORLARDA YALLIG'LANISHGA QARSHI SITOKINLARGA TA'SIRI
##article.subject##:
YuIK, teri orqali koronar aralashuv, yallig'lanishga qarshi sitokinlar, rozuvastatin, fenofibrik kislota, IL-6, TNF-a, CRO##article.abstract##
Bugungi kunda yurak ishemik kasalligi (YuIK) keksa bemorlarda o'limning asosiy sababi bo'lib qolmoqda. Biroq, yurak ishemik kasalligi bo'lgan bemorlarning hayot sifatini yaxshilash uchun samarali teri orqali koronar aralashuvlar amalga oshiriladi. Tadqiqotimizning maqsadi teri osti koronar aralashuvni o'tqizgan, yurak ishemik kasalligi bo'lgan keksa bemorlarda rosuvastatin va uning fenofibrin kislota bilan kombinatsiyasining yallig'lanishga qarshi samaradorligini iborat edi. Ushbu maqolada bemorlarning aksariyati keksalar ekanligi va koronar arteriya kasalligi, barqaror angina III-IV FK tashxisi qo'yilganligi tahlil qilindi. 109 nafar bemor tekshirildi, ularning o'rtacha yoshi 65,3±0,4 yoshni tashkil etdi. 20 mg dozada rosuvastatin va 145 mg dozada fenofibrik kislota bilan ikki marta lipidlarni kamaytiradigan terapiyani qabul qilishda 6 va 12 oydan keyin lipid profilining darajasini tahlil qilib, ular me'yoriy qiymatlarga yaqinlashdilar. Barcha yallig'lanishga qarshi sitokinlar - IL-6, TNF-a va CRP darajasi pasayish tendentsiyasiga ega, bu statinlarning pleiotrop ta'sirini isbotlaydi. Shuningdek, uzoq muddatli kuzatuv davrida hayot sifati va yakuniy nuqtalari ko'rsatkichlari o'rganildi.
Библиографические ссылки
Ambrosova T.N. Therapeutic correction of atherogenic dyslipidemia in metabolic syndrome. International medical journal. 2013.
Barsukov A.V., Talantseva M.S., Sveklina T.S. and others. Lipid-lowering therapy in elderly patients. The focus is on statins and prognosis. Arterial hypertension. 2011.17(5). pp. 415-424.
Bugaenko V.V. Gender features of diagnosis, course and treatment of coronary heart disease. Ukrainian cardiology journal. 2015. №6. pp.100-112.
Ivanov D. O., Aleksandrovich Yu. S., Pshenisnov K. V. et al. Diseases of the cardiovascular system as a cause of death in the Russian Federation: ways to solve the problem. Medicine and healthcare organization, 2019. 4(2), pp.4-12.
Kutishenko N.P., Tolpygina S.N., Lukina Yu.V. Efficiency and safety of drug therapy in primary and secondary prevention of cardiovascular diseases. Rational pharmacotherapy in cardiology 2011. 7(5S), pp.2-72.
Marinina E. S., Nagibin O. A. Scientific substantiation of the main ways of preventing cardiovascular diseases. UNIVERSUM: medicine and pharmacology, 2018. (2 (47)), pp. 4-9.
Okrugin S.A., Garganeeva A.A., Kuzheleva E.A. Evaluation of the influence of myocardial infarction in history and preinfarction state on the duration of the prehospital stage of acute myocardial infarction. complex problems of cardiovascular diseases. 2016.5(1). pp.55-59.
Soleeva S.Sh. Statins and pro-inflammatory cytokines in coronary heart disease after coronary stenting. Journal of Cardiorespiratory Research. 2022. No. 3(2).
Ellamonov S.N., Tashkenbaeva E.N., Abdieva G.A. et al. Factors of progression of arterial hypertension in patients with comorbidity with type 2 diabetes mellitus. Journal of Cardiorespiratory Research, 2021. 2(2).
Word Health Organization. Preventing chronic disease: A vital investment //http:// www.who.int./chp/chronic disease report.
